Home / News / International / Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma is expecting to receive an approval for its first biosimilar product in the US in the next 12-18 months, while in Europe, the company hopes a green signal by 2022.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

x

Check Also

Educational institutions built with Indian assistance inaugurated

Educational institutions built with Indian assistance inaugurated

In Nepal, three educational institutions built with the Indian assistance of 126.60 ...

Facebook blocks 30 accounts to prevent tampering in US midterm elections

Facebook blocks 30 accounts to prevent tampering in US midterm elections

Facebook said Monday it had blocked some 30 accounts on its platform ...